Reference
Medicines and Healthcare products Regulatory Agency. Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) Internet Document : 17 Jun 2021. Available from: URL: https://www.gov.uk/drug-safety-update/atezolizumab-tecentriqv-and-other-immune-stimulatory-anti-cancer-drugs-risk-of-severe-cutaneous-adverse-reactions-scars
Rights and permissions
About this article
Cite this article
Atezolizumab: risk of severe cutaneous adverse reactions. Reactions Weekly 1862, 1 (2021). https://doi.org/10.1007/s40278-021-98119-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-98119-y